Alma Lasers
Suzanna Djukic has a strong background in operations and management across a variety of healthcare and cosmetic industries. Suzanna most recently served as the Director of Operations at Alma Lasers starting in February 2023. Prior to that, they worked at Chicago Cosmetic Surgery and Dermatology as a Cosmetic Operations staff member, from June 2022 to February 2023. The majority of their experience comes from their roles as Chief Operating Officer at Private Practice In Plastic And Aesthetic Surgery from September 2019 to June 2022, and as Practice Director/Chief Operating Officer at California Fertility Partners from June 2015 to May 2019. Suzanna also gained experience as a Practice Manager at Lincoln Park Smiles from January 2013 to November 2014, and as a Business Practice Manager at ORA Studios from October 2008 to May 2012. Prior to that, they worked as a Business Office Manager at The Dental Specialists, Implant Solutions from August 2005 to October 2008, and as a Clinical Manager/Business Manager at Michigan Avenue Dental Associates from May 2002 to August 2005.
Suzanna Djukic received their Bachelor of Science degree in Public Health from Indiana University. Suzanna attended the university from 1995 to 2000.
This person is not in any offices
Alma Lasers
1 followers
Alma Lasers is a global innovator of laser, light-based, radiofrequency and ultrasound solutions for the aesthetic and surgical markets. Alma Lasers has been at the forefront of multi-technology systems, revolutionizing existing treatment methods and working to serve the varied and growing needs of both patients and practitioners around the world.With offices, R&D and manufacturing facilities on three continents and distributors around the world, Alma's mission is to provide modular, cost-effective and high-performance systems based on the very latest clinical research and cutting-edge technology. They enable practitioners to offer safe, effective and profitable aesthetic and surgical treatments to their patients, while allowing patients to benefit from the capabilities of state-of-the-art, clinically proven technologies and methods.